This is a StreetInsider.com Premium Only Page

(ARQT) – Trader Talk

Feb 1, 2022 11:31 AM Arcutis (ARQT) Seborrheic Dermatitis Opportunity is Underappreciated, Represents a Free Call Option on Stock - Mizuho

Jan 20, 2022 04:21 PM Arcutis Biotherapeutics' (ARQT) Pipeline is Strong and Diversified, roflumilast cream Has High Approval Chance, Multiple Catalysts to Look Forward to - Mizuho

Jan 18, 2022 06:13 AM

Jul 30, 2020 06:47 AM

Jul 29, 2020 08:37 AM

Jul 28, 2020 06:52 AM